Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit. The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs. Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way. They expect significant manufacturing increases to occur, starting in the back half of the year. CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.” Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter. |
Courteney Cox reveals her late Friends coBradley Cooper branded 'desperate' after studio submits his TWOIraqi parliament fails to elect new speakerString of pars weren't enough for Collin Morikawa as others shot birdies at PGA ChampionshipBrest secures final automatic Champions League spot in French league, PSG wins without MbappéIn Saudi Arabia, an allWill AI replace doctors who read XInside the race for the world's first MILEMan City wins record fourth straight Premier League title after 3China's Xizang to transmit 2 bln kWh of clean energy out of region in 2024